Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Obsidian Therapeutics, Inc.OBX · Entity 4898 | Director | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Obsidian Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02 | Direct | 37,653 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653 F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date January 10, 2025 · Filed January 10, 2025
Section 16 reporting ended · disclosed 2025-01-10. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2023 Filed Jan 18, 2023 21:57 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 7,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-001078 · form4-01182023_090137.xml · nonDerivative · entry 1 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the company's common stock. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionRestricted Stock Units · Derivative | 7,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010644 · form4-10182022_011054.xml · derivative · entry 3 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,186 Underlying: Common Stock · 7,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the company's common stock. F2 · derivative.exercise_date: On January 21, 2022, the reporting person was granted 59,500 restricted stock units. The shares underlying the restricted stock units vest over two years, with 25% of the shares vested on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. F2 · derivative.expiration_date: On January 21, 2022, the reporting person was granted 59,500 restricted stock units. The shares underlying the restricted stock units vest over two years, with 25% of the shares vested on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Tax withholdingCommon Stock | 2,184 | $5.61 | $12,252.24 |
DisclosureSEC source: 0001415889-22-010644 · form4-10182022_011054.xml · nonDerivative · entry 2 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,763 Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 7,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-010644 · form4-10182022_011054.xml · nonDerivative · entry 1 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the company's common stock. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:16 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionRestricted Stock Units · Derivative | 14,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007764 · form4-07192022_010715.xml · derivative · entry 3 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,624 Underlying: Common Stock · 14,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the company's common stock. F2 · derivative.exercise_date: On January 21, 2022, the reporting person was granted 59,500 restricted stock units. The shares underlying the restricted stock units vest over two years, with 25% of the shares vesting on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. F2 · derivative.expiration_date: On January 21, 2022, the reporting person was granted 59,500 restricted stock units. The shares underlying the restricted stock units vest over two years, with 25% of the shares vesting on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:16 UTC | Generation Bio Co. GBIO · Entity 67174 | Tax withholdingCommon Stock | 4,367 | $7.18 | $31,355.06 |
DisclosureSEC source: 0001415889-22-007764 · form4-07192022_010715.xml · nonDerivative · entry 2 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,509 Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:16 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 14,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-007764 · form4-07192022_010715.xml · nonDerivative · entry 1 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of the company's common stock. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantRestricted Stock Units · Derivative | 59,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-000748 · form4-01252022_040114.xml · derivative · entry 2 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 Underlying: Common Stock · 59,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the company's common stock. F3 · derivative.exercise_date: The shares underlying the restricted stock units vest over two years, with 25% of the shares vesting on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. F3 · derivative.expiration_date: The shares underlying the restricted stock units vest over two years, with 25% of the shares vesting on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 119,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001415889-22-000748 · form4-01252022_040114.xml · derivative · entry 1 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires 2032-01-21 F1 · derivative.exercise_date: This option was granted on January 21, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on January 21, 2023 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 6,100 | $0.00 Strike: $30.73 | $0.00 |
DisclosureSEC source: 0001415889-21-000544 · form4-02052021_020215.xml · derivative · entry 2 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Underlying: Common Stock · 6,100 shares Expires 2031-02-02 F2 · derivative.exercise_date: This option was granted on February 3, 2021. The shares underlying the option vest over four years, with 25% of the shares vesting on January 22, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 22, 2021 Filed Feb 5, 2021 22:03 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 32,823 | $0.00 Strike: $30.25 | $0.00 |
DisclosureSEC source: 0001415889-21-000544 · form4-02052021_020215.xml · derivative · entry 1 Norkunas Matthew · CIK 0001816836 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,823 Underlying: Common Stock · 32,823 shares Expires 2031-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2021. The shares underlying the option vest over four years, with 25% of the shares vesting on January 22, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 20:40 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0000899243-20-020385 · doc4.xml · derivative · entry 1 Norkunas Matthew · CIK 0001816836 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2030-07-21 F1 · derivative.exercise_date: The option was granted on July 22, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 22, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.